---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-183449"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2025-08-19T23:59:59+00:00"
generated_at: "2026-05-17T11:28:09.235650+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health: Crofelemer cuts TPN needs in MVID/SBS; FDA outlines sNDA path for breast cancer

## Summary
- All 7 proposals approved at Aug 19 annual meeting; directors elected, stock plan amended, share issuances authorized.
- Initial proof-of-concept data: crofelemer reduced TPN up to 27% in MVID patient and up to 12.5% in SBS-IF patient.
- FDA meeting aligned on regulatory pathway to complete supplemental NDA for crofelemer in metastatic breast cancer (orphan population).
- Company plans to seek license partnerships for orphan indications to generate non-dilutive funding.

## SEC filing metadata
- accession: 0001193125-25-183449
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2025-08-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000119312525183449/0001193125-25-183449-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000119312525183449/d947561d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-183449
- JSON: https://secwatch.observer/filing/0001193125-25-183449.json
- Plain text: https://secwatch.observer/filing/0001193125-25-183449.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.